Respiratory

RSS

Cerecor reports phase II proof-of-concept data for CERC-002 in COVID-19 ARDS

Jan. 7, 2021

Windtree initiates phase II trial of lucinactant for COVID-19-associated acute lung injury

Jan. 7, 2021

Enterprise Therapeutics divulges ANO1 activators

Jan. 5, 2021

HY-1702 found to be protective in LPS-induced respiratory distress syndrome in mice

Jan. 4, 2021

GlaxoSmithKline plc identifies new mTOR inhibitors

Jan. 4, 2021

Arcturus selects ARCT-032 as development candidate for cystic fibrosis

Dec. 31, 2020

Phase IIb/III trial of Zyesami for respiratory failure in critical COVID-19 completes enrollment

Dec. 30, 2020

National Institute of Pharmaceutical R&D describes M3 antagonists/beta2-adrenoceptor agonists

Dec. 28, 2020

Acticor initiates phase II trial of glenzocimab to treat COVID-19 related ARDS

Dec. 23, 2020

SOURCE trial of tezepelumab in severe asthma misses primary endpoint

Dec. 23, 2020